COVID-19 vaccination outcomes among patients with dermatomyositis: a multicentered analysis

Pakhchanian, Haig; Saud, Ahmad; Raiker, Rahul; Kardeş, Sinan; Aggarwal, Rohit; Gupta, Latika

doi:10.1007/s10067-022-06081-7

Cited by 5 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is due to the cycle of autoimmunity triggering reactions and vice versa. Similar results have been demonstrated in other autoimmune diseases 7 . Among IIM subgroups, minor ADEs appear to be increased in DM and less frequent in IBM.…”

Section: Discussionsupporting

confidence: 88%

“…Similar results have been demonstrated in other autoimmune diseases. 7 Among IIM subgroups, minor ADEs appear to be increased in DM and less frequent in IBM. However, it is important to note that subset analyses by vaccine type were limited by small numbers, preventing firm conclusions.…”

Section: Discussionmentioning

confidence: 96%

“…Although recent studies have included rheumatic disorders, significant gaps exist in understanding the safety of COVID‐19 vaccination in patients with rare diseases, such as idiopathic inflammatory myopathies (IIMs) 4–6 . The study on vaccination‐related adverse events (ADEs) in dermatomyositis (DM) from the TrinetX (Cambridge, MA) database has looked at the overall 1‐, 30‐, and 60‐day ADEs after three vaccines (BNT162b2, mRNA‐1273, and Ad26.COV.2.S) used in USA 7 . The study included a total of 6104 vaccinated dermatomyositis (DM) patients from the USA.…”

Section: Introductionmentioning

confidence: 99%

“…[4][5][6] The study on vaccination-related adverse events (ADEs) in dermatomyositis (DM) from the TrinetX (Cambridge, MA) database has looked at the overall 1-, 30-, and 60-day ADEs after three vaccines (BNT162b2, mRNA-1273, and Ad26.COV.2.S) used in USA. 7 The study included a total of 6104 vaccinated dermatomyositis (DM) patients from the USA. DM patients demonstrated a higher rate of ADEs compared with age-matched healthy controls (HCs).…”

mentioning

confidence: 99%

See 3 more Smart Citations

COVID‐19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies

et al. 2022

Self Cite

View full text Add to dashboard Cite

Introduction/Aims We studied COVID‐19 vaccination‐related adverse events (ADEs) 7‐days post‐vaccination in patients with idiopathic inflammatory myopathies (IIMs) and other systemic autoimmune and inflammatory disorders (SAIDs). Methods 7‐day vaccine ADEs were collected in an international patient self‐reported e‐survey. Descriptive statistics and multivariable regression were performed. Results 10,900 respondents [1227 IIMs; 4640 SAIDs; 5033 healthy controls (HCs), median age 42 (IQR 30‐55) years, 74% female, 45% Caucasian, 69% completely vaccinated] were analysed. 76.3% IIMs patients reported minor and 4.6% major ADEs. Patients with active IIMs reported more frequent major [OR 2.7 (1.04‐7.3)] and minor [OR 1.5 (1.1‐2.2)] ADEs than inactive IIMs. Rashes were more frequent in IIMs [OR‐2.3(1.2‐4.2)] than HCs. ADEs were not impacted by steroid dose, although hydroxychloroquine and intravenous/subcutaneous immunoglobulins were associated with a higher risk of minor ADEs [OR 1.9 (1.1‐3.3), OR 2.2 (1.1‐4.3)]. Overall, ADEs were less frequent in inclusion body myositis (IBM) and BNT162b2 (Pfizer) vaccine recipients Discussion 7‐day post‐vaccination ADEs were comparable in patients with IIMs, SAIDs, and HCs, except for a higher risk of rashes in IIMs. Patients with DM, active disease may be at higher risk, and IBM patients at lower risk of specific ADEs. Overall, the benefit of preventing severe COVID‐19 through vaccination likely outweighs the risk of vaccine‐related ADEs Our results may inform future guidelines regarding COVID‐19 vaccination in patients with SAIDs, and specifically in IIMs. Studies to evaluate long‐term outcomes and disease flares are needed to shed more light on developing future COVID‐19 vaccination guidelines. This article is protected by copyright. All rights reserved.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

COVID‐19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Regarding safety, a large study found that DM patients did not have a difference in risk for immediate anaphylaxis at one-day post-immunisation compared to HC (113). Additionally, at 30 days post-vaccination, vaccinated DM patients did not experience a difference in risk for adverse events of special interest (AESI), breakthrough infection (BI), or all-cause hospitalisation (ACH) compared to HC.…”

Section: Covid-19 and Vaccinationsmentioning

confidence: 99%

Idiopathic inflammatory myopathies: one year in review 2022

Cardelli

Zanframundo

Cometi

et al. 2023

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of disorders in which chronic inflammation of the skeletal muscle, leading to muscle weakness, is a common feature. Different phenotypes have been identified within the IIM spectrum based on extra-muscular manifestations, immunology, muscle histology, responsiveness to therapy, and prognosis. The pathogenesis, classification, treatment, and prognosis of the different IIM subtypes are subject to active discussion and research. This review highlights the most relevant literature published on this topic over the last year.

show abstract

Incidence, features, and outcome of disease relapse after COVID‐19 vaccination in patients with idiopathic inflammatory myopathies

et al. 2023

View full text Add to dashboard Cite

Introduction/Aims Vaccination against coronavirus disease 2019 (COVID‐19) is relatively safe in patients with idiopathic inflammatory myopathies (IIM); however, myositis flares following vaccination have been poorly studied. We aimed to evaluate the frequency, features, and outcomes of disease relapses in patients with IIM following COVID‐19 vaccination. Methods A cohort of 176 IIM patients were interviewed after the third wave of the COVID‐19 pandemic and followed prospectively. Relapses were determined using the disease state criteria and the outcome of the flares with myositis response criteria, calculating the total improvement score (TIS). Results A total of 146 (82.9%) patients received a vaccination, 17/146 (11.6%) patients had a relapse within 3 mo, and 13/146 (8.9%) patients within 1 mo. The relapse rate of unvaccinated patients was 3.3%. Three months after the post‐vaccination relapses, 70.6% of the patients (12/17) achieved an improvement of disease activity (average TIS score: 30 ± 15.81; seven minor, five moderate, and zero major improvements). Six months after flares improvement was detected in 15/17(88.2%) of relapsed patients (average TIS score: 43.1 ± 19.53; 3 minimal, 8 moderate, and 4 major). Forward stepwise logistic regression analysis revealed that the active state of myositis at the time of injection (p < .0001; odds ratio, 33; confidence interval, 9–120) was significantly associated with the occurrence of a relapse. Discussion A minority of the vaccinated IIM patients had a confirmed disease flare after COVID‐19 vaccination and the majority of the relapses improved after individualized treatment. An active disease state at the time of vaccination probably contributes to the increased risk of a post vaccination myositis flare.

show abstract

COVID-19 vaccination outcomes among patients with dermatomyositis: a multicentered analysis

Cited by 5 publications

References 10 publications

COVID‐19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies

COVID‐19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies

Idiopathic inflammatory myopathies: one year in review 2022

Incidence, features, and outcome of disease relapse after COVID‐19 vaccination in patients with idiopathic inflammatory myopathies

Contact Info

Product

Resources

About